| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors (NCT05010096) | M.D. Anderson Cancer Center | 2022-03-22 |
| Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit (NCT05091632) | M.D. Anderson Cancer Center | 2021-05-04 |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors (NCT04879121) | M.D. Anderson Cancer Center | 2021-04-30 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (NCT04387071) | University of Southern California | 2021-04-29 |
| Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer (NCT05058339) | M.D. Anderson Cancer Center | 2021-04-27 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor (NCT04800627) | M.D. Anderson Cancer Center | 2021-03-29 |
| Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer (NCT04697524) | University of California, San Francisco | 2021-01-26 |
| PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning (NCT04889144) | Fred Hutchinson Cancer Center | 2021-01-01 |
| Testing the Safety of CB-5339 in Patients With Cancer (NCT04372641) | National Cancer Institute (NCI) | 2020-06-18 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (NCT04068194) | National Cancer Institute (NCI) | 2020-04-07 |
| Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers (NCT04082572) | M.D. Anderson Cancer Center | 2019-10-31 |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (NCT03907475) | National Cancer Institute (NCI) | 2019-07-16 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers (NCT03868423) | Sameek Roychowdhury | 2019-03-20 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (NCT03583255) | M.D. Anderson Cancer Center | 2018-06-29 |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer (NCT02321501) | M.D. Anderson Cancer Center | 2016-06-22 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types (NCT06075524) | Mayo Clinic | 2015-06-15 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |